Photocure, the Norwegian specialty pharmaceutical company focused in dermatology and cancer, is pleased to invite to a lunch presentation on Monday 28 March 2011 to further present the opportunitites for Lumacan through the license agreement with Salix Pharmaceticals Inc.

The CEO of Salix, Carolyn Logan, and the VP of R&D of Salix, Bill Forbes, will present Salix' plans for development and commercialization of Lumacan, as well as how they perceive the market potential for Lumacan.

The presentation will be held at Shippingklubben, Haakon VIIs gate 1, Oslo.

Lunch is served from 11:15 am CET, the presentations start at 11:30 and the session is expected to close at 01:00 pm CET.

The program for is as follows:

·         Welcome remarks and introduction by CEO of Photocure, Kjetil Hestdal

·         Presentation of Salix, by CEO of Salix, Carolyn Logan

·         US colon cancer market and the Lumacan opportunity, by VP of R&D Salix, Bill Forbes

·         Q&A and closing remarks

Please register your attendance at Photocure by Friday 25 March 1pm. Contact person: Grete Faye-Schjøll (e-mail: gfs@photocure.no / phone +47 22 06 22 10 / fax +47 22 06 22 18).

Christian Fekete

CFO

Photocure ASA

Tel: + 47 916 42 938, E-mail: cf@photocure.no

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)